Speaking to a crowd of young professionals, Murashko said the country is "clearly moving along the path of expanding scientific and clinical research" and highlighted the new ranking as evidence of that progress.
He urged emerging specialists to join laboratories and clinics, framing the surge in trial activity as a national priority that could boost both public health and the economy.
Murashko also warned that chronic diseases cost Russia an estimated 2.5 trillion roubles each year, noting that more than half of people beyond working age suffer at least one non‑communicable disease, 20 % already have a disability, and only a quarter rate their health as good.
Looking ahead, the minister cautioned that longer life expectancy could drive cancer incidence up to 50 % worldwide over the next 25 years, making cancer a long‑term threat for Russia as well.
He set a target to raise the proportion of Russians leading a healthy lifestyle by 1.5 times by 2030, emphasizing that there is no "magic product"—neither dietary supplements nor sports nutrition—capable of substituting a balanced daily diet.
Analytics firm Headway Company reported that domestic pharmaceutical firms dominate the Russian clinical‑research market, accounting for 82 % of all developments since the start of the year, with Russian sponsors securing 304 trial approvals to date.